Rehovot (Israel), May 31, 2010

The Company will discuss its strategic partnerships and innovative in-house pipeline, including first-in-class Topical Minocycline.

Foamix Ltd. will present at the UBS 2010 Global Specialty Pharmaceuticals Conference, which will be held from June 2-3 in London, UK.

Dov Tamarkin, Ph.D., Foamix's CEO, will speak on Thursday June 3, 2010 at 9:30 pm London time. He will provide an overview of the company, its technologies and strategic partnerships with pharmaceutical companies. He will further provide an update on Foamix’s innovative drug development pipeline, which includes the first-in-class Topical Minocycline, as well as other proprietary products. Foamix’s Topical Minocycline is currently in Phase II clinical trials in a number of dermatological conditions, with a projected launch in 2013-14.

The Company’s Topical Minocycline will also be developed for a number of ophthalmic and women’s health applications, through partnerships with leading companies in these fields.

About UBS:

Headquartered in Zurich and Basel, Switzerland, UBS is a client-focused financial services firm that offers a combination of wealth management, asset management and investment banking services on a global and regional basis. By delivering a full range of advice, products and services to its private, corporate and institutional clients, UBS aims to generate sustainable earnings, create value for its shareholders, and become the choice of clients worldwide.

The UBS 2010 Global Specialty Pharmaceuticals Conference will take place from Wednesday, 2 - Thursday, 3 June 2010 at the UBS Offices, 1 Finsbury Avenue, London EC2M 2PP.

About Foamix Ltd:

Headquartered in Rehovot, Israel, Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foam and OilGel™ products for prescription, OTC and cosmetic applications. By incorporating drugs in foam and OilGel™, Foamix creates advanced, patent protected products with improved convenience, higher compliance and better efficacy. The company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.

Foamix partners with leading pharmaceutical companies, including Galderma, Bayer, Dr. Reddy's and Ferndale Laboratories.

Foamix further has its own in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is in clinical development for the treatment of rosacea, acne and skin infections; Topical Minocycline has further applications in the fields of ophthalmic therapy and gynecology.

To date, Foamix has twenty three issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company has an additional 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

For additional information please see www.foamix.co.il